Aims Vigabatrin is a new antiepileptic medication consisting of a racemic mixture of 50% active S enantiomer and 50% inactive R enantiomer. Since patients suffering from epilepsy may become pregnant, it is important to understand the extent of placental transfer of such medication. Methods During steady-state, vigabatrin enantiomer concentrations were measured in maternal and umbilical blood and in breast milk of two patients. Results The concentration ratios from the umbilical vein to maternal plasma were R50.068, S50.16; 4h25 min after drug administration (case 1) and R51.39, S50.91; 9h after drug administration (case 2). The milk5plasma concentration ratio was lower than 1 at pre dose sampling in both cases, as well as 3 and 6 h post dose in one case. An estimate of the maximum amount of R and S enantiomers of vigabatrin that a suckling infant would ingest in a day is 3.6% and 1% of the weight-adjusted daily dose respectively. Conclusions These results would suggest a slow placental transfer of the vigabatrin enantiomers and that the quantity ingested through milk is small.
Introduction answers to these issues. Vigabatrin is an anticonvulsant drug, supplied as a racemic mixture of two enantiomers. The S enantiomer possesses Methods pharmacological activity, whereas the R enantiomer is inactive. At peak, (t max R50.8±0.2 h, S51±0.5 h) concenPatients trations of the R enantiomer exceeded concentrations of The data were not collected through a formal planned the S enantiomer, with an approximate ratio of 251 [1, 2] . prospective study. Nevertheless both patients were fully The mean terminal half-life ranged from 6 to 8 h for both involved in the importance of the investigation and freely enantiomers in adults [1] . In children (8.7±3.8 years) the gave their consent to participate. mean half-lives were similar for the S enantiomer Case 1: A 32 year old Caucasian woman, received 1000 mg (5.47±1.93 h) and for the R enantiomer (5.68±2.86 h). In twice daily vigabatrin and 200 mg three times daily younger children (12.1±5.9 months) the half-life was carbamazepine (slow release) for previously intractable partial shorter for the R enantiomer (2.87±1.03 h) compared with seizures in her final trimester. the S enantiomer (5.65±1.52 h) [2] .
Case 2: A 33 year old Caucasian woman, received 1000 mg A medication that has been found to be essential in the twice daily vigabatrin throughout her pregnancy. The clinical management of a woman, is difficult to withdraw patient gave birth to a 3.2 kg newborn of 41 weeks during a pregnancy. Vigabatrin often falls within this gestation. category and it is vital to understand the placental transfer of such a drug, in order to evaluate any possible risks involved. Although in vitro data of the placental transfer of Sample managements the enantiomers of vigabatrin is available [3] , in vivo data are
Immediately following birth a blood sample was collected needed to accurately assess the potential of foetal exposure.
from the mother and the umbilical vein (case 1) and from Likewise, after confinement, any decision about breast the umbilical vein and artery (case 2). feeding needs information on the amount of a drug which On the seventh day, post partum, maternal venous blood might pass into the milk, in particular if the drug could and breast milk were concomitantly collected at predose and have an effect on the infant's developing central nervous 3 and 6 h post-dose (case 1). On the eighth day post partum system. maternal venous blood was collected at predose, breast milk at predose and 3 and 6 h post-dose. The milk was collected from both breasts (30 ml) using a breast-pump prior to 
feeding (case 2).
A. Tran et al.
the foetal compartment was also evidenced (case 2) as the Analytical procedure concentrations in the umbilical artery (R54.80 mg l −1 and S52.13 mg l −1 ) were similar to those of the umbilical vein. The concentrations of the enantiomers of vigabatrin were measured in plasma using a GC-MS method as previously
Comparing case 1 (ratio F/M=R50.068, S50.16) to case 2 (ratio F/M=R51.39, S50.91) it can be inferred that described [2] ; the enantiomers of vigabatrin being analysed as N-trifluoroacetyl-O-propyl ester derivatives. The proplacental transfer varies with time of administration. This suggests a slow transfer, the equilibrium being obtained at cedure for the analysis in milk required an additional cleanup step which involved passing the sample extract through least 9 h after the administration of the drug. The rate of placental transfer of the two enantiomers a conditioned Dowex microcolumn and subsequent elution of the analytes of interest. Cow's milk was used as the blank might be slightly different since the ratio F/M for the S active enantiomer is twice that of the R enantiomer at 4 h matrix for the validation of the analytical method for use with human milk samples. Whilst the composition of cow's post dose (case 1) and 40% lower 9 h post dose (case 2). milk differs, predominantly in protein content, from human milk, deproteinisation is the first step in the extraction Excretion into breast milk procedure (100 ml of trichloroacetic acid 6% for 200 ml of milk). The detailed analytical method was as follows: the The data are given in Table 2 . Whatever the time of collection predose or postdose (3 deproteinized milk sample was added on a preconditionned column [Dowex 50W×8 (Fluka): 200 mg, washed with and 6 h), the milk plasma (M/P) concentration ratio was always lower than 1 in case 1 for both enantiomers (R HCl (3n; 1 ml) and water (1 ml)] washed with water (1 ml) and eluted with NH 4 OH (3n; 1 ml). The eluate was enantiomer 50.62, 0.14, 0.49 and S enantiomer 0.22, 0.042, 0.20 at predose, 3 and 6 h postdose, respectively). Similar evaporated to dryness at 40°C under a stream of nitrogen. Following this, the procedure was similar to that used results were obtained in case 2 at predose collection (M/P R enantiomer50.86 ( left breast) and 0.87 (right breast); S for plasma.
For plasma, the standard curve was linear from 0.5 to enantiomer 0.12 (left breast) and 0.19 (right breast). The data suggested that each enantiomer behaved 50 mg l −1 . The coefficients of variation were less than 12.7% at all concentrations for both enantiomers. For milk differently. The M/P for the R enantiomer was always higher than the M/P for the S enantiomer ( predose, 3 h the standard curve was linear from 0.2 to 10 mg l −1 . The coefficients of variation were less than 6% for both and 6 h postdose) suggesting a lower transfer of the active S form into the milk. However no difference between the enantiomers. The limits of quantification were 0.5 mg l , the maximum dose he would receive can be estimated. In case 1, using the maximum Placental transfer milk concentration the amount would be for the R enantiomer 333 mg kg −1 day −1 (2.22 mg l −1 ×150 ml) i.e. The data are shown in Table 1 .
In case 1 the maternal plasma concentrations of both less than 2.0% of the maternal dose and for the S enantiomer 108 mg kg −1 day −1 (0.721 mg l −1 ×150 ml) i.e. less than enantiomers were measured 4 h 25 min after dosing (R511.5 mg l −1 , S56.40 mg l −1 ). These were higher than 0.6% of the maternal dose. In case 2 the same calculation would give 601 mg kg −1 day −1 (4.01 mg l −1 ×150 ml) and in case 2 where concentrations were measured 9 h after dosing (R53.50 mg l −1 , S52.19 mg l −1 ): this reflected the 160 mg kg −1 day −1 (1.07 mg l −1 ×150 ml), or 3.6% and 0.96% of the maternal dose for R and S enantiomer different sampling times.
The umbilical vein concentrations were either lower in respectively (the maternal weight was assumed to be 60 kg ). case 1 (R50.78 mg l −1 , S51 mg l −1 ) or similar to maternal concentrations in case 2 (R54.87 mg l −1 , S51.99 mg l −1 ). Discussion The placental transfer assessed by the umbilical vein to maternal plasma concentration ratio (F/M) showed that the Since vigabatrin has a short half-life, it can be assumed that steady-state was achieved in both mothers. pseudo equilibrium was not achieved in case 1 (F/M= R50.068, S50.16) but was obtained in case 2 (F/M= At steady-state, the rise in concentration of the enantiomers of vigabatrin in the foetus is slow, which indicates R51.39, S50.91) in the maternal foetal unit. Steady state in that vigabatrin crosses the placenta slowly as with most lipid insoluble molecules. Vigabatrin has a low molecular weight (129), is water soluble and unbound to plasma proteins. It is transferred by simple diffusion (Fick's law) through a hydrophilic pathway. As hydrophilic molecules do not permeate the cell membrane of the trophoblast, they are thought to cross the placenta by an extracellular route [4] . These results are in agreement with in vitro data which described a low placental transfer of both enantiomers [3] . Regarding the excretion of vigabatrin into breast milk the limited data would suggest that when vigabatrin is taken by a nursing mother, the quantity ingested through the milk is small. It would be at maximum 4% of the weight-adjusted maternal daily dose. Such a dose is unlikely to have a significant pharmacological activity in an infant following regular breast feeding from a mother on normal therapeutic doses of vigabatrin. Table 2 Excretion into breast milk. 
